Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Background Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, has...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer Jg. 120; H. 2; S. 165 - 171
Hauptverfasser:	Mazzaferro, Vincenzo, El-Rayes, Bassel F., Droz dit Busset, Michele, Cotsoglou, Christian, Harris, William P., Damjanov, Nevena, Masi, Gianluca, Rimassa, Lorenza, Personeni, Nicola, Braiteh, Fadi, Zagonel, Vittorina, Papadopoulos, Kyriakos P., Hall, Terence, Wang, Yunxia, Schwartz, Brian, Kazakin, Julia, Bhoori, Sherrie, de Braud, Filippo, Shaib, Walid L.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 22.01.2019 Nature Publishing Group
Schlagworte:	631/67/1059/602 692/4028/67/1504/1329/1326 Adult Aged Aged, 80 and over Alkaloids - administration & dosage Alkaloids - adverse effects Asthenia Biomedical and Life Sciences Biomedicine Cancer Research Chemotherapy Cholangiocarcinoma Cholangiocarcinoma - drug therapy Cholangiocarcinoma - genetics Cholangiocarcinoma - pathology Clinical Trials as Topic Disease control Drug Resistance Enzyme inhibitors Epidemiology Fatigue Female Fibroblast growth factor receptor 2 Fibroblast growth factor receptors Gene fusion Humans Hyperphosphatemia Kinases Male Middle Aged Molecular Medicine Mutation Next-generation sequencing Oncogene Proteins, Fusion - drug effects Oncogene Proteins, Fusion - genetics Oncology Patients Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Receptor, Fibroblast Growth Factor, Type 2 - genetics Toxicity Tumors
ISSN:	0007-0920, 1532-1827, 1532-1827
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!